Publicaciones en colaboración con investigadores/as de University of Calgary (34)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. Profiling the immune landscape in mucinous ovarian carcinoma

    Gynecologic Oncology, Vol. 168, pp. 23-31

  4. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  2. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

2021

  1. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Translational psychiatry, Vol. 11, Núm. 1, pp. 182

  2. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  3. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718

  4. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Journal of Hematology and Oncology

  5. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

    Journal of Cancer Research and Clinical Oncology, Vol. 147, Núm. 2, pp. 619-631

  6. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  7. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

    American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130

  8. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

    Annals of Hematology, Vol. 100, Núm. 4, pp. 1065-1077

  9. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region with Cortical and Subcortical Morphology and Cognition

    JAMA Psychiatry, Vol. 77, Núm. 4, pp. 420-430

  2. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Haematologica, Vol. 105, Núm. 2, pp. 468-477

  3. Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

    Molecular Psychiatry, Vol. 25, Núm. 3, pp. 584-602

  4. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

  5. Prognostic gene expression signature for high-grade serous ovarian cancer

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250